Esophageal Cancer
1,030
191
240
437
Key Insights
Highlights
Success Rate
84% trial completion
Published Results
121 trials with published results (12%)
Research Maturity
437 completed trials (42% of total)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
8.3%
86 terminated out of 1030 trials
83.6%
-3.0% vs benchmark
8%
83 trials in Phase 3/4
28%
121 of 437 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 437 completed trials
Clinical Trials (1030)
18F-AraG PET/CT as a Non-Invasive Imaging Biomarker for Chemoradiation Treatment Response in Esophageal Cancer
Luso-Cor Stent Compared to Other Endoscopic Techniques for Management of Fistulas and Anastomotic Dehiscences(ES-LCCE-UDFM)
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
Integrated Cancer Repository for Cancer Research
CPAP or BiPAP for Motion Mitigation During Radiotherapy
High-Flow Nasal Cannula for Preventing Hypoxia During Sedated Endoscopy in High-Risk Obstructive Sleep Apnea Patients
Tumor Cell and DNA Detection in the Blood, Urine and Bone Marrow of Patients With Solid Cancers
Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)
Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)
DESTINY-PANTUMOUR04
Exercise Training After Upper Gastrointestinal Cancer Surgery
PD-1 Inhibitor Combined With Neoadjuvant Chemoradiotherapy Plus Surgery for Locally Advanced ESCC (NEOCRTEC2101)
Lead-212 PSV359 Therapy for Patients With Solid Tumors
Nutrition Intervention Trials in Linxian Follow-up Study
CA-4948 in Combination With FOLFOX/PD-1 Inhibitor +/- Trastuzumab for Untreated Unresectable Gastric and Esophageal Cancer
Comparison of Nab-Paclitaxel Versus Paclitaxel in Neoadjuvant Immunochemotherapy Therapy for Esophageal Squamous Cell Carcinoma: A Retrospective IPTW-Adjusted Analysis
Effect of Feeding Jejunostomy on Sarcopenia in Patients With Esophageal Cancer
Phase 1 Study of PF-08046033 in Advanced Solid Tumors
Open Versus Laparoscopically-assisted Esophagectomy for Cancer
Adjuvant Trastuzumab Deruxtecan (Enhertu) & Nivolumab For Patients Who Are Disease Free After Completion of Trimodality Treatment For HER-2+ Cancers of Esophagus & Gastroesophageal Junction